API | omigapil

omigapil Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Omigapil is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD). ^Wikipedia

Chemistry

SMILES: CN(CC#C)CC1=Cc2ccccc2Oc3ccccc13
InChIKey: QLMMOGWZCFQAPU-UHFFFAOYSA-N
Mol. Mass: 275.35
ALogP: 3.9 Partition coefficient
ChEMBL Molecule:
omigapil

More Chemistry

Pharmacology

Mechanism of Action:
- Glyceraldehyde-3-phosphate dehydrogenase (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cgp 3466 | cgp-3466 | cgp3466b | cgp 3466b | cgp-3466b | dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine | omigapil | tch346 | tch 346 | tch-346

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Amyotrophic Lateral Sclerosis (Phase 2)

Muscular Dystrophies (Phase 1)

Parkinson Disease (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue